Ognomy raises $20M to scale AI-driven sleep apnea care across all 50 states
What's the deal? Ognomy Sleep, a virtual sleep medicine platform, has closed a $20 million Series A round led by Catalyst InvestorsDealroom has a profile for this one. Try Dealroom →, with participation from Blue Heron CapitalDealroom has a profile for this one. Try Dealroom →.
The Buffalo-based startup will use the funds to expand its AI-enabled clinical platform, add wearable integrations, and grow what it calls one of the nation's largest virtual sleep medicine networks.
Founded by sleep physician Daniel RifkinDealroom has a profile for this one. Try Dealroom →, Ognomy guides patients through the full sleep apnea journey — from referral and home testing to diagnosis and long-term adherence support — across all 50 states.
Why now? Sleep apnea affects more than one billion people globally, yet specialty care remains fragmented and hard to access.
Ognomy has logged 85,000+ virtual visits, earned 80+ Net Promoter Scores, and won the 2026 MedTech Breakthrough Award for Best Overall SleepTech Solution. Other backers include Impellent VenturesDealroom has a profile for this one. Try Dealroom →, Launch NYDealroom has a profile for this one. Try Dealroom →, Excell PartnersDealroom has a profile for this one. Try Dealroom →, Upstate Biotech Ventures, and the University of Buffalo.
What could go wrong? Scaling AI and automation while preserving the “human connection at the center of care” is a delicate balance, as Rifkin acknowledges.
Therapy adherence is notoriously difficult in sleep medicine, and a virtual-first model must sustain its market-leading compliance as patient volumes climb.
The signal: Dealroom classifies Ognomy as a breakout-stage company, and this Series A — led by investment fund Catalyst InvestorsDealroom has a profile for this one. Try Dealroom → with backing from Blue Heron CapitalDealroom has a profile for this one. Try Dealroom → and Impellent VenturesDealroom has a profile for this one. Try Dealroom → — reflects growing investor conviction that virtual specialty care can scale nationally. With a stated mission to reach one billion patients worldwide, the startup is betting that sleep apnea becomes a recognised gateway into the broader cardiometabolic health ecosystem.
Read more: EIN Presswire
Image credit: Generated with Gemini
